<DOC>
	<DOC>NCT02414958</DOC>
	<brief_summary>Comparison of 2 doses of empagliflozin vs placebo in patients already using either an insulin regimen of MDI or CSII. Randomisation to 3 treatments arms (equal assignment) following a screening period, an optimisation period and a run-in period. 52 week double-blind treatment period, and 3 week follow-up period.</brief_summary>
	<brief_title>Empagliflozin as Adjunctive to inSulin thErapy in Type 1 Diabetes Over 52 Weeks (EASE-2)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Empagliflozin</mesh_term>
	<criteria>Inclusion criteria: Male or female patient receiving insulin for the treatment of documented diagnosis of T1DM for at least 1 year at the time of Visit 1 Fasting Cpeptide value of &lt; 0.7 ng/mL (0.23 nmol/L) at Visit 2 measured by the central laboratory Use of, and be willing, based on the Investigator's judgement, to continue throughout the duration of the trial, either: MDI of insulin consisting of at least one basal insulin injection and at least three daily bolus injections OR CSII of any insulin type, with at least 5 months experience of using CSII prior to Visit 1 HbA1c &gt;/= 7.5% and &lt;/= 10.0% at Visit 5 measured by the central laboratory Age &gt;/= 18 years at Visit 1 Additional inclusion criteria may apply Exclusion criteria: History of T2DM, maturity onset diabetes of the young (MODY), pancreatic surgery or chronic pancreatitis Pancreas, pancreatic islet cells or renal transplant recipient T1DM treatment with any other antihyperglycaemic drug (e.g. metformin, alphaglucosidase inhibitors, GLP1 analogues, SGLT2 inhibitors, pramlintide, inhaled insulin, premixed insulins etc.) except subcutaneous basal and bolus insulin within 3 months prior to Visit 1 Occurrence of severe hypoglycaemia involving coma/unconsciousness and/or seizure that required hospitalisation or hypoglycaemiarelated treatment by an emergency physician or paramedic within 3 months prior to Visit 1 and until randomisation Occurence of DKA within 3 months prior to Visit 1 and until randomisation Additional exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>